Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · IEX Real-Time Price · USD
21.46
-0.32 (-1.47%)
At close: Jul 19, 2024, 4:00 PM
21.27
-0.19 (-0.89%)
Pre-market: Jul 22, 2024, 4:40 AM EDT
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 40.33, with a low estimate of 22 and a high estimate of 95. The average target predicts an increase of 87.93% from the current stock price of 21.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DNLI stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 5 | 5 | 5 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $28 → $29 | Buy | Maintains | $28 → $29 | +35.14% | Jul 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +342.68% | May 8, 2024 |
| Wedbush | Wedbush | Buy Maintains $31 → $30 | Buy | Maintains | $31 → $30 | +39.79% | May 8, 2024 |
| Stifel | Stifel | Hold Maintains $26 → $22 | Hold | Maintains | $26 → $22 | +2.52% | May 8, 2024 |
| UBS | UBS | Strong Buy Maintains $70 → $32 | Strong Buy | Maintains | $70 → $32 | +49.11% | Apr 9, 2024 |
Financial Forecast
Revenue This Year
48.94M
from 330.53M
Decreased by -85.19%
Revenue Next Year
110.48M
from 48.94M
Increased by 125.76%
EPS This Year
-2.73
from -1.06
EPS Next Year
-2.65
from -2.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 130.2M | 385.6M | 513.6M | 1.1B | 1.7B |
| Avg | 48.9M | 110.5M | 190.4M | 436.0M | 717.4M |
| Low | n/a | n/a | n/a | 102.9M | 176.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -60.6% | 688.0% | 364.9% | 477.1% | 286.2% |
| Avg | -85.2% | 125.8% | 72.4% | 129.0% | 64.5% |
| Low | - | - | - | -46.0% | -59.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.49 | -1.24 | -0.67 | 2.09 | 4.70 |
| Avg | -2.73 | -2.65 | -1.92 | 2.03 | 4.57 |
| Low | -3.23 | -3.25 | -3.36 | 1.95 | 4.39 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 131.7% |
| Avg | - | - | - | - | 125.1% |
| Low | - | - | - | - | 116.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.